investors.arcusbio.comArcus Biosciences - Investors & Media

Arcus Biosciences - Investors & MediaAbout Arcus Leadership Board of Directors Scientific Advisory Board Contact Us Editorials Careers Investors & Media Press Releases Events & Presentations Events Calendar Corporate Presentation Stock Information Analyst Coverage Stock Information SEC Filings Corporate Governance Governance Documents Management Team Board of Directors Committee Composition Contact Investor Relations Contact Investor Relations FAQs Email Alerts Follow Us X LinkedIn Sign Up For Updates Our Science People and science are a beautiful combination. Arcus is at the forefront of designing combination therapies on a relentless pursuit to investigate new medicines for people with cancer. Pipeline Clinical Candidates Anti-TIGIT domvanalimab Adenosine Axis etrumadenant quemliclustat Anti-PD-1 (zimberelimab) HIF-2⍺ Inhibitor (casdatifan) Anti-CD39 (AB598) AXL Inhibitor (AB801) Clinical Trials Investigator Sponsored Expanded Access Program Publications Our Science Pipeline Clinical Candidates Overview Anti-TIGIT domvanalimab Adenosine Axis etrumadenant quemliclustat Anti-PD-1 (zimberelimab) HIF-2⍺ Inhibitor (casdatifan) Anti-CD39 (AB598) AXL Inhibitor (AB801) Clinical Trials Clinical Trials Investigator Sponsored Expanded Access Program Publications Investors & Media About Arcus Leadership Board of Directors Scientific Advisory Board Contact Us Editorials Careers Investors & Media Press Releases Events & Presentations Events Calendar Corporate Presentation Stock Information Analyst Coverage Stock Information SEC Filings Corporate Governance Governance Documents Management Team Board of Directors Committee Composition Contact Investor Relations Contact Investor Relations FAQs Email Alerts Follow Us X LinkedIn Sign Up For Updates Investor Overview Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. Download PDF (opens in new window) CLICK HERE TO VIEW OUR CLINICAL CANDIDATES CLICK HERE TO VIEW OUR CLINICAL CANDIDATESOur Molecules Learn More domvanalimab An Fc-silent anti-TIGIT antibody being evaluated in multiple combinations in Phase 2 Learn More etrumadenant A dual adenosine A2a/A2b receptor agonist being evaluated in Phase 1 and Phase 2 studies across multiple indications, including lung, colon and prostate cancer. Learn More quemliclustat A small molecule CD73 inhibitor in Phase 1 and Phase 2 studies for lung and pancreatic cancers. Learn More zimberelimab An anti-PD1 monoclonal antibody being studied in various combinations across the portfolio, including multiple Phase 3 studies to support the potential approval of zimberelimab plus domvanalimab in lung and gastrointestinal cancers. Learn More AB521 A small-molecule inhibitor of the hypoxic transcriptional regulator HIF-2a that has demonstrated potent antitumor activity in xenograft models of cancer. AB521 is currently in Phase 1 clinical trials and is being developed for clear cell renal cell carcinoma. Learn MoreOUR PARTNERSHIPS Partnerships and collaborations enable our ability to accelerate the global investigation of novel combination treatments that address major unmet needs and have the potential to improve outcomes for people with cancer around the world. Strategic partners to advance global development and commercialization activities: Gilead and Arcus have a 10-year all-in partnership that included a significant capital investment and equity stake by Gilead into Arcus. Gilead holds co-development and co-commercialization rights to zimberelimab (anti-PD1 antibody) and an option to license current and future molecules. Taiho has exercised option rights in Japan and other countries in Asia (excluding China) for the majority of Arcus’ clinical portfolio ̶ including domvanalimab, zimberelimab, etrumadenant, and AB308. Clinical collaborations to explore novel combinations Arcus is interested in clinical collaborations that evaluate novel combinations of Arcus molecules with other companies’ medicines or diagnostics to expand our understanding of important pathways and facilitate global access to expedite development and commercialization. AstraZeneca and Arcus have a clinical collaboration on Pacific-8 a Phase III study evaluating our anti-TIGIT antibody domvanalimab plus durvalumab (Imfinzi®) for stage 3 non-small cell lung cancer with curative intentLatest Press Releases View All Press Releases Featured Presentation Latest Events View All Events Our Partnerships Partnerships and collaborations enable our ability to accelerate the global investigation of novel combination treatments that address major unmet needs and have the potential to improve outcomes for people with cancer around the world. Strategic partners to advance global development and commercialization activities: Gilead and Arcus have a 10-year all-in partnership that includes a significant capital investment and equity stake by Gilead into Arcus. Gilead holds co-development and co-commercialization rights to zimberelimab, domvanalimab, etrumadenant and quemliclustat and an option to license current and future molecules. Taiho has exercised option rights in Japan and other countries in Asia (excluding China) for the majority of Arcus’ clinical portfolio, including domvanalimab, zimberelimab and etrumadenant. Taiho has chosen to participate in two ongoing Phase 3 trials of domvanalimab combinations, STAR-121 in NSCLC and STAR-221 in upper GI cancer. Clinical collaborations to explore novel combinations Arcus is interested in clinical collaborations that evaluate novel combinations of Arcus molecules with other companies’ medicines or diagnostics to expand our understanding of important pathways and facilitate global access to expedite development and commercialization. AstraZeneca and Arcus have a clinical collaboration on Pacific-8 a Phase III study evaluating our anti-TIGIT antibody domvanalimab plus durvalumab (Imfinzi®) for stage 3 non-small cell lung cancer with curative intent In December 2023, Arcus and Exelixis announced a clinical trial collaboration evaluating AB521, a small molecule inhibitor of the oxygen-sensing transcription factor HIF-2⍺, in combination with Exelixis’ tyrosine kinase inhibitor in patients with advanced solid tumors including clear cell renal cell carcinoma (ccRCC). Investor Contact [email protected] Investor Email Alerts To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time. * Required Email Address * Mailing Lists * Press Releases Events SEC Filings EOD Stock Quote Email Alert Sign Up Confirmation Explore More Read our latest press releases and announcements Browse Join forces with us on our mission to defeat cancer Connect Arcus clinical trials are currently enrolling Sign up Arcus Biosciences is a registered trademark of Arcus Biosciences, Inc. © Arcus Biosciences, Inc. All rights reserved. 3928 Point Eden Way, Hayward, CA 94545Our Science Editorials Careers Investors & Media Contact Terms of Use Sitemap Pipeline Clinical Trials PublicationsContactPrivacy Policy Washington Health Data Privacy Policy Cookie Policy Terms of UseSitemapDO NOT SELL/SHARE MY PERSONAL INFORMATION Powered By Q4 Inc. 5.122.0.3 (opens in new...